Selux Diagnostics Gets $2.8 Million Grant for Phenotyping Platform

Selux Diagnostics has received a $2.8 million grant from NIH to help the company bring to market its Next Generation Phenotyping (NGP) platform for rapid antimicrobial susceptibility testing.

The Boston, Mass.-based company, which recently completed its first clinical trial and submitted the results to the FDA, received a Breakthrough Device designation from the FDA for the NGP platform.

Selux CEO Steve Lufkin said the NIH funding will help it scale up manufacturing and carry out another clinical trial to compare NGP’s performance against older phenotyping systems.